Wednesday, October 28, 2026Eastern Time · Updated through the dayRSS

The daily wire on therapeutic peptides. Regulatory, research, compounding and the incretin race, condensed.

Patients with diabetes deserve more choices than GLP-1s | Opinion

MH

By Maren Holt · Senior Reporter, GLP-1

Oct 23 05:05 ETSource: USA Today

From the source

Patients with diabetes deserve more choices than GLP-1s | Opinion

Read at usatoday.com

Source URL https://www.usatoday.com/story/opinion/2026/10/23/weight-loss-glp-1-diabetes-ozempic-zepbound-mounjaro/92348958007/

Prescribed peptides from $99/moSee all →